U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077798) titled 'Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection' on July 11.
Brief Summary: Vessels that encapsulate tumor clusters (VETC) are a novel invasive metastatic factor in hepatocellular carcinoma (HCC), operating independently of the epithelial-mesenchyme transition (EMT). The presence of VETC is associated with a higher rate of postoperative recurrence in HCC patients, indicating a more aggressive biological behavior.Improving the prognosis for VETC-positive patients is a critical issue in clinical oncology.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Ca...